Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 211-220 of 3089 for cancer

Edit search filters
  1. Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer. (PROTA)

    Rochester, MN

  2. A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

    Rochester, MN, Jacksonville, FL

  3. Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

    Rochester, MN

  4. First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients with Advanced Cancers

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study

    Jacksonville, FL

  7. Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

    Scottsdale/Phoenix, AZ

  8. A Study Assessing the Effectiveness and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced Triple Negative Breast Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ

  9. A Study to Evaluate Adjuvant Ado-Trastuzumab Emtansine (T-DM1) in HER2 Positive Breast Cancer

    Rochester, MN

  10. Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

    Rochester, MN

.

Mayo Clinic Footer